Minerva gastroenterology最新文献

Application of artificial intelligence combined with MDT teaching model in colorectal cancer training teaching. 人工智能结合MDT教学模式在结直肠癌培训教学中的应用。

IF 1.9

Minerva gastroenterology Pub Date : 2024-11-19 DOI: 10.23736/S2724-5985.24.03784-7

Jiawen Liu, Ning Zhang, Bo Li, Shouliang Cai

引用次数: 0

Pancreatic necrosis: a scoping review. 胰腺坏死：范围综述。

IF 1.9

Minerva gastroenterology Pub Date : 2024-10-31 DOI: 10.23736/S2724-5985.24.03658-1

Anthony Rainho, Mira Sridharan, Daniel S Strand

{"title":"Pancreatic necrosis: a scoping review.","authors":"Anthony Rainho, Mira Sridharan, Daniel S Strand","doi":"10.23736/S2724-5985.24.03658-1","DOIUrl":"10.23736/S2724-5985.24.03658-1","url":null,"abstract":"Acute pancreatitis (AP) is a commonly encountered GI diagnosis, accounting for 275,000 hospital admissions annually in the United States alone. Pancreatic necrosis (PN) is the most common complication of AP, and the development of PN is associated with significant morbidity and increased mortality. This expert review evaluates the evidence-based management of symptomatic PN from the era of maximal open pancreatic necrosectomy in the late 1990s though the modern paradigm of minimally invasive and endoscopic interventions. The authors present the retrospective and controlled data behind the \"step-up approach\" to PN treatment and discuss the application of current society guidance. Evidence based management of PN is characterized by early supportive care, and treatment by minimally invasive intervention when a patient is critically ill or persistently symptomatic. Appropriate choices when intervention is required include percutaneous drainage, minimally invasive surgery, and/or endoscopic treatment. The transition from open maximal necrosectomy to minimally invasive intervention has resulted in improved outcomes for patients, including gains in mortality, significant morbidity, and cost. The ideal precision management strategy for an individual patient remains an area of increasing understanding.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected. 在治疗炎症性肠病时，从静脉注射到皮下注射维多珠单抗的转换率低于预期。

IF 1.9

Minerva gastroenterology Pub Date : 2024-10-29 DOI: 10.23736/S2724-5985.24.03712-4

Antonio Tursi, Giammarco Mocci, Walter Elisei, Edoardo Savarino, Giovanni Maconi, Franco Scaldaferri, Alfredo Papa

{"title":"Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected.","authors":"Antonio Tursi, Giammarco Mocci, Walter Elisei, Edoardo Savarino, Giovanni Maconi, Franco Scaldaferri, Alfredo Papa","doi":"10.23736/S2724-5985.24.03712-4","DOIUrl":"https://doi.org/10.23736/S2724-5985.24.03712-4","url":null,"abstract":"Background: It is known that the subcutaneous (SC) route administration of biologic drugs has several potential benefits for patient and the healthcare system. Since few real-world data are available yet about the rate of transition from intravenous (IV) to SC Vedolizumab (VDZ) in the Italian population, we assessed this rate in a large cohort of inflammatory bowel disease (IBD) patients under remission receiving IV VDZ as standard of care in a real-world setting.Methods: Searching who was asked to switch from IV VDZ To SC VDZ, and assessing the rate of acceptance. The Mayo score in Ulcerative colitis (UC) and the Harvey-Bradshaw Index (HBI) in Crohn's Disease (CD) scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results: Overall, 238 patients (145 with UC and 93 with CD) having remission ≥1 year with VDZ were asked to switch to VDZ SC, but only nine patients (four with UC and five with CD, 3.78% of the total population to which the switch was proposed) agreed to switch. No difference were found between patients accepting and patients refusing switching about the reasons of the choice. All patients accepting switch maintained clinical remission during the follow-up, and no adverse events were recorded.Conclusions: Switching to SC route is a safe and effective choice for IBD patients under remission using VDZ. However, this choice is not preferred by the majority of patients on stable remission under IV VDZ.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role and mechanisms of long non-coding RNA HOTAIR in regulating the Wnt/β-catenin signaling pathway in gastric cancer cells and its impact on tumor invasion and metastasis. 长非编码RNA HOTAIR在调控胃癌细胞Wnt/β-catenin信号通路中的作用和机制及其对肿瘤侵袭和转移的影响

IF 1.9

Minerva gastroenterology Pub Date : 2024-10-29 DOI: 10.23736/S2724-5985.24.03760-4

Shunping Mao

引用次数: 0

Evaluation of the effect of moxibustion therapy combined with press needle stimulation of bilateral Zusanli (ST36) and Neiguan (PC6) points on gastric motility recovery in patients with gastroparesis after pancreatoduodenectomy. 灸疗联合按针刺激双侧足三里（ST36）和内关（PC6）穴对胰十二指肠切除术后胃瘫患者胃动力恢复的影响评估

IF 1.9

Minerva gastroenterology Pub Date : 2024-10-29 DOI: 10.23736/S2724-5985.24.03774-4

Yueying Huang, Bo Huang, Lingling Liu

引用次数: 0

E. coli 5C: a probiotic effective for preventing post-colonoscopy gastrointestinal discomfort? 大肠杆菌 5C：一种能有效预防结肠镜检查后胃肠道不适的益生菌？

IF 1.9

Minerva gastroenterology Pub Date : 2024-10-11 DOI: 10.23736/S2724-5985.24.03772-0

Francesco DI Pierro, Massimiliano Cazzaniga, Alexander Bertuccioli, Chiara M Palazzi, Ilaria Cavecchia, Mariarosaria Matera, Nicola Zerbinati

引用次数: 0

Successful endoscopic decompression of an intramural duodenal hematoma secondary to pancreatitis causing duodenal and common bile duct obstruction. 成功为继发于胰腺炎导致十二指肠和胆总管梗阻的十二指肠内血肿进行内镜减压。

IF 1.9

Minerva gastroenterology Pub Date : 2024-09-26 DOI: 10.23736/S2724-5985.24.03724-0

Connor Ryan, Robert S O'Neill, David Williams

引用次数: 0

Impact of early enteral nutrition support on immune function in patients undergoing radical rectal cancer surgery. 早期肠内营养支持对直肠癌根治术患者免疫功能的影响。

IF 1.9

Minerva gastroenterology Pub Date : 2024-09-26 DOI: 10.23736/S2724-5985.24.03754-9

Juan Li, Xiangrong Zhu, Tingting Shao, Lisong Teng

引用次数: 0

Pediatric gastroenteritis: an integrated analysis of epidemiology, clinical manifestations, diagnostic methods, and multi-level therapeutic interventions. 小儿肠胃炎：流行病学、临床表现、诊断方法和多层次治疗干预的综合分析。

IF 1.9

Minerva gastroenterology Pub Date : 2024-09-18 DOI: 10.23736/S2724-5985.24.03739-2

Xuejing Geng, Xiansheng Cao, Wei Zhou, Jixiang Jiang, Xue Zhou, Hong Liu

引用次数: 0

Monitoring the psychopathological profile of inflammatory bowel disease patients treated with biological agents: a pilot study. 监测接受生物制剂治疗的炎症性肠病患者的心理病理特征：一项试点研究。

IF 1.9

Minerva gastroenterology Pub Date : 2024-09-18 DOI: 10.23736/S2724-5985.24.03719-7

Antonio M D'Onofrio, Lodovico M Balzoni, Gaspare F Ferrajoli, Federica DI Vincenzo, Daniele Napolitano, Elisa Schiavoni, Georgios D Kotzalidis, Alessio Simonetti, Marianna Mazza, Ilenia Rosa, Mauro Pettorruso, Gabriele Sani, Antonio Gasbarrini, Franco Scaldaferri, Giovanni Camardese

{"title":"Monitoring the psychopathological profile of inflammatory bowel disease patients treated with biological agents: a pilot study.","authors":"Antonio M D'Onofrio, Lodovico M Balzoni, Gaspare F Ferrajoli, Federica DI Vincenzo, Daniele Napolitano, Elisa Schiavoni, Georgios D Kotzalidis, Alessio Simonetti, Marianna Mazza, Ilenia Rosa, Mauro Pettorruso, Gabriele Sani, Antonio Gasbarrini, Franco Scaldaferri, Giovanni Camardese","doi":"10.23736/S2724-5985.24.03719-7","DOIUrl":"https://doi.org/10.23736/S2724-5985.24.03719-7","url":null,"abstract":"Background: Biological agents were found to alter the psychopathological profile of a small subgroup of patients treated for a variety of conditions, including inflammatory bowel disease (IBD) and psychiatric disorders. The association between the administration of biological agents and psychopathology needs to be further investigated.Methods: In this naturalistic prospective cohort study, patients with IBD were assigned to two treatment groups, i.e., a biological agent (which also included tofacitinib) or conventional therapy. Clinician-administered scales were used to assess psychosomatic symptoms (Hamilton Depression Rating Scale [Ham-D], Hamilton Anxiety Rating Scale [Ham-A], Young Mania Rating Scale [YMRS], and Brief Psychiatric Rating Scale [BPRS]) and disease activity (Mayo Score and Harvey-Bradshaw Index [HBI]) at baseline, after one, three, and six months of treatment. Each group was assessed for the course of their scores during the observation period at each assessment point.Results: Patients on biological drugs who completed three months of treatment (N.=32) and six months of treatment (N.=20) scored significantly lower on the Mayo compared to baseline. Patients on conventional treatment obtained significant drops from baseline on the HBI after one and three months of treatment (N.=30) and also at the six-month endpoint (N.=11). Both groups showed no improvement or worsening on the psychiatric rating scales.Conclusions: In this study, we found no evidence of psychiatric symptom worsening, as some literature would suggest. Our data suggest that the use of biological agents in IBD is safe.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0